Compare
Biogen vs Bristol-Myers Squibb
MonkScore ranges and fundamentals, side by side
Key facts
Biogen and Bristol-Myers Squibb: key facts
- In fiscal 2025, Biogen Inc. reported revenue of $9.8B and net income of $1.3B.
- In fiscal 2025, Bristol-Myers Squibb Company reported revenue of $48.2B and net income of $7.1B.
- Biogen Inc.'s revenue fell 2.8% a year from fiscal 2021 to fiscal 2025.
- Bristol-Myers Squibb Company's revenue grew 1.0% a year from fiscal 2021 to fiscal 2025.
- Biogen Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
- Bristol-Myers Squibb Company's free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
- In the twelve months to 30 September 2026, Biogen Inc. reported revenue of $10.3B and net income of $348.0M.
- In the twelve months to 30 September 2026, Bristol-Myers Squibb Company reported revenue of $50.0B and net income of $9.2B.
Side by side
Biogen and Bristol-Myers Squibb, side by side
Each figure is in the company's reporting currency, with its fiscal year or the date of its last report.
| Figure | Biogen Inc.NASDAQ:BIIB | Bristol-Myers Squibb CompanyNYSE:BMY |
|---|---|---|
| MonkScore | ||
| MonkScore range | 50–60as of October 2026 | 80–90as of October 2026 |
| Sector rank | 352 of 628 in Healthcare | 137 of 628 in Healthcare |
| How this score is madeDisclaimer | ||
| Profile | ||
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Latest fiscal year | ||
| Revenue | $9.8BFY 2025 | $48.2BFY 2025 |
| Net income | $1.3BFY 2025 | $7.1BFY 2025 |
| Free cash flow | $2.1BFY 2025 | $12.8BFY 2025 |
| Operating cash flow | $2.2BFY 2025 | $14.2BFY 2025 |
| Total debt | $6.9BFY 2025 | $47.1BFY 2025 |
| Cash | $3.0BFY 2025 | $10.2BFY 2025 |
| Last 12 months | ||
| Revenue | $10.3Bto 30 September 2026 | $50.0Bto 30 September 2026 |
| Net income | $348.0Mto 30 September 2026 | $9.2Bto 30 September 2026 |
| Free cash flow | $2.3Bto 30 September 2026 | $9.3Bto 30 September 2026 |
| Operating cash flow | $2.2Bto 30 September 2026 | $10.7Bto 30 September 2026 |
| Total debt | $7.8Bto 30 September 2026 | $42.9Bto 30 September 2026 |
| Cash | $1.3Bto 30 September 2026 | $9.6Bto 30 September 2026 |
Company pages
Each company on its own
MonkStreet provides research, not investment advice.